ES2300849T3 - Pirazolopirimidinas. - Google Patents

Pirazolopirimidinas. Download PDF

Info

Publication number
ES2300849T3
ES2300849T3 ES04798915T ES04798915T ES2300849T3 ES 2300849 T3 ES2300849 T3 ES 2300849T3 ES 04798915 T ES04798915 T ES 04798915T ES 04798915 T ES04798915 T ES 04798915T ES 2300849 T3 ES2300849 T3 ES 2300849T3
Authority
ES
Spain
Prior art keywords
co2r
alkyl
optionally substituted
haloalkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES04798915T
Other languages
English (en)
Inventor
Andrew Bell
David Brown
David Bull
David Fox
Ian Pfizer Marsh
Andrew Morrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2300849T3 publication Critical patent/ES2300849T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula (I): (Ver fórmula) en la que: R 1 es un grupo cíclico elegido entre R A , R B , R C y R D , cada uno de los cuales está opcionalmente sustituido con uno o más grupos R 7 ; R 2 es hidrógeno o alquilo C1-C2; R 3 y R 4 son, cada uno de ellos independientemente, alquilo C1-C8, alquenilo C2-C8, alquinilo C2-C8 o cicloalquilo C3-C10, cada uno de los cuales está opcionalmente sustituido con uno o más grupos R 8 , o R E que está opcionalmente sustituido con uno o más grupos R 9 , o hidrógeno; o -NR 3 R 4 forma R F que está opcionalmente sustituido con uno o más grupos R 10 ; R 5 es -Y-CONR 15 R 16 ; R 6 , que puede estar unido a N 1 o N 2 , es alquilo C1-C6, haloalquilo C1-C6, alquenilo C2-C6 o alquinilo C2-C6, cada uno de los cuales está opcionalmente sustituido con alcoxi C1-C6, haloalcoxi C1-C6 o un grupo cíclico elegido entre R J , R K , R L y R M , o R 6 es R N , cicloalquilo C3-C7 o halocicloalquilo C3-C7, cada uno de los cuales está opcionalmente sustituido con un alcoxi C1-C6 o haloalcoxi C1-C6, o R 6 es hidrógeno; R 7 es halo, alquilo C1-C6, haloalquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, cicloalquilo C3-C10, halocicloalquilo C3-C10, fenilo, OR 12 , OC(O)R 12 , NO2, NR 12 R 13 , NR 12 C(O)R 13 , NR 12 CO2R 14 , C(O)R 12 , CO2R 12 , CONR 12 R 13 o CN; R 8 es halo, fenilo, alcoxi C1-C6-fenilo, OR 12 , OC(O)R 12 , NO2, NR 12 R 13 , NR 12 C(O)R 13 , NR 12 CO2R 14 , C(O)R 12 , CO2R 12 , CONR 12 R 13 , CN, R G o R H , los dos últimos de los cuales están opcionalmente sustituidos con uno o más grupos R 9 ; R 9 es alquilo C1-C6, haloalquilo C1-C6 o CO2R 12 ; R 10 es halo, cicloalquilo C3-C10, halocicloalquilo C3-C10, fenilo, OR 12 , OC(O)R 12 , NO2, NR 12 R 13 , NR 12 C(O)R 13 , NR 12 CO2R 14 , C(O)R 12 , CO2R 13 , CONR 12 R 13 , CN, oxo, alquilo C1-C6 o haloalquilo C1-C6, los dos últimos de los cuales están opcionalmente sustituidos con R 11 ; R 11 es fenilo, NR 12 R 13 o NR 12 CO2R 14 ; R 12 y R 13 son, cada uno de ellos independientemente, hidrógeno, alquilo C1-C6 o haloalquilo C1-C6; R 14 es alquilo C1-C6 o haloalquilo C1-C6; R 15 y R 16 se eligen, cada uno de ellos independientemente, entre...
ES04798915T 2003-11-24 2004-11-19 Pirazolopirimidinas. Active ES2300849T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0327323.2A GB0327323D0 (en) 2003-11-24 2003-11-24 Novel pharmaceuticals

Publications (1)

Publication Number Publication Date
ES2300849T3 true ES2300849T3 (es) 2008-06-16

Family

ID=29797726

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04798915T Active ES2300849T3 (es) 2003-11-24 2004-11-19 Pirazolopirimidinas.

Country Status (11)

Country Link
US (1) US20070105877A1 (es)
EP (1) EP1689752B1 (es)
JP (1) JP2007512317A (es)
AT (1) ATE387449T1 (es)
BR (1) BRPI0416678A (es)
CA (1) CA2545196A1 (es)
DE (1) DE602004012146T2 (es)
ES (1) ES2300849T3 (es)
GB (1) GB0327323D0 (es)
MX (1) MXPA06005824A (es)
WO (1) WO2005049617A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286731A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
NZ564187A (en) 2005-05-12 2010-03-26 Pfizer Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
NL2000291C2 (nl) * 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
US9682952B2 (en) * 2012-09-04 2017-06-20 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2-6-dione and methods of preparation thereof
RU2019112740A (ru) 2016-09-30 2020-11-02 АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи P2x3 и/или p2x2/3 соединения и способы

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3951980A (en) * 1974-05-09 1976-04-20 Stanford Research Institute 3-Substituted-8-methyl-3,8-diazabicyclo[3.2.1]octanes
US4282361A (en) * 1978-03-16 1981-08-04 Massachusetts Institute Of Technology Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines
US5091431A (en) * 1988-02-08 1992-02-25 Schering Corporation Phosphodiesterase inhibitors
US5442044A (en) * 1991-01-04 1995-08-15 Pfizer Inc. Orally active renin inhibitors
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
US6184338B1 (en) * 1997-08-27 2001-02-06 Fmc Corporation Anionic polymerization initiators containing tertiary amine functionality, their chain extended analogues, and processes for using the same
HU230154B1 (hu) * 1997-11-12 2015-09-28 Bayer Intellectual Property Gmbh Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására
AU3514200A (en) * 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
US6465486B1 (en) * 1999-03-12 2002-10-15 Ortho-Mcneil Pharmaceutical, Inc. Pyridyl/quinolinyl imidazoles
DE19942474A1 (de) * 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
US6548509B2 (en) * 1999-10-22 2003-04-15 Neurogen Corporation 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
EP1244668B1 (en) * 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
US20010047013A1 (en) * 2000-03-10 2001-11-29 Fengrui Lang Process for the preparation of arylamines
DE10031584A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
DE10058662A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Pyrazolo[4,3-d]pyrimidinen
WO2002049651A1 (de) * 2000-12-19 2002-06-27 Merck Patent Gmbh Pharmazeutische formulierung enthaltend pyrazolo[4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate
US20020127593A1 (en) * 2001-03-12 2002-09-12 Regents Of The University Of California Fluorescence assay for DNA modifying enzymes
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US6432957B1 (en) * 2001-06-29 2002-08-13 Kowa Co., Ltd. Piperazine derivative
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
OA13050A (en) * 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.

Also Published As

Publication number Publication date
JP2007512317A (ja) 2007-05-17
BRPI0416678A (pt) 2007-02-13
WO2005049617A1 (en) 2005-06-02
EP1689752A1 (en) 2006-08-16
ATE387449T1 (de) 2008-03-15
EP1689752B1 (en) 2008-02-27
US20070105877A1 (en) 2007-05-10
DE602004012146D1 (en) 2008-04-10
MXPA06005824A (es) 2006-08-11
GB0327323D0 (en) 2003-12-31
CA2545196A1 (en) 2005-06-02
DE602004012146T2 (de) 2009-03-19

Similar Documents

Publication Publication Date Title
AR053994A1 (es) Sulfonilpirrolidinas sustituidas procedimiento para su preparacion y su uso como medicamentos
CO5640118A2 (es) 5,7-diaminopirazol[4,3-d]piridinas utiles en el tratamiento de la hipertension
ES2300849T3 (es) Pirazolopirimidinas.
AR082562A1 (es) Derivados de isoxazolina como agentes antiparasitarios
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
AR053149A1 (es) Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis
ECSP10010368A (es) Derivados de urea de tetrahidroquinoxalina, su preparación
AR088534A1 (es) Composiciones plaguicidas y procesos relacionados con dichas composiciones
CO6150144A2 (es) Inhibidores de proteina tirosina fosfatasa humana y metodos de uso
AR055635A1 (es) Uso de sulfonanilidas como herbicidas
AR048669A1 (es) Derivados biciclicos de bisamida
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
CO6160231A2 (es) Compuestos de isoindolina 5-substituidos
DOP2006000045A (es) Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica
GT200500238A (es) Fenilaminotiazoles sustituidos y su uso
ECSP099062A (es) Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a
SV2011003825A (es) Nuevos derivados de acilaminobenzamida
DK2032370T3 (da) Reversible thermochrome sammensætninger
CO6150147A2 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
MX2010007019A (es) Compuestos de bencimidazol.
CO6190531A2 (es) Derivados de heteroaril-pirrolidinil- y-piperidinil-cetona
AR060912A1 (es) Benzamidinas insecticidas
AR063636A1 (es) Derivados de indol y de benzofurano-2-carboxamida
ES2523302T3 (es) Colorantes azoicos
AR069340A1 (es) Antagonistas del receptor de angiotensina ii